Personalized Results 1 - 10 of about 838 for BIBW 2992. (0.35 seconds)
News - The EGFR/HER2 Tyrosine Kinase Inhibitor BIBW 2992 Well ...
The EGFR/HER2 Tyrosine Kinase Inhibitor BIBW 2992 Well Tolerated: Presented at AACR-NCI-EORTC.
www.docguide.com/news/content.nsf/ news/8525697700573E18852570C0004A44E6 - 80k - Cached - Similar pages
News - A 2-Week-On, 2-Week-Off Schedule Appears Optimal for BIBW ...
BIBW 2992 is a highly selective potent irreversible dual inhibitor of the ... They concluded that BIBW 2992 was safe in patients given a 2-week-on, ...
www.docguide.com/news/content.nsf/ news/8525697700573E18852570C0006232FF - 79k - Cached - Similar pages
ASCO - Phase 1 study with BIBW 2992, an irreversible dual tyrosine ...
A phase 1 study of orally administered BIBW 2992 was performed to determine its safety, ... In cycle 1 and 2, BIBW 2992 plasma PK analysis was performed. ...
www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM... - 57k - Cached - Similar pages
[PDF]
1 of 3 “A Phase I Open-Label Dose Escalation Study of Continuous ...
File Format: PDF/Adobe Acrobat - View as HTML
Treatment with BIBW 2992 in Patients with Advanced Solid Tumors” ... period, the patient will be given BIBW 2992 at the same dose as other patients in the ...
www.csmc.edu/pdf/wwwbibwb.pdf - Similar pages
[PDF]
1 of 2 “A Phase I Open-Label Dose Escalation Study of Continuous ...
File Format: PDF/Adobe Acrobat - View as HTML
Treatment with BIBW 2992 in Patients with Advanced Solid Tumors” ... The particular growth factor receptors that BIBW 2992, research drug, ...
www.csmc.edu/pdf/wwwbibwa.pdf - Similar pages
Boehringer Ingelheim Deutschland: Sci_Pub
Methods BIBW-2992 was administered orally once daily starting at 10 mg/day ... Exploring two different dosing schedules, BIBW 2992 was continuously orally ...
www.boehringer-ingelheim.de/ forschung/scipub/sci_pub.jsp?gebiet=Onkologie - 195k - Cached - Similar pages
Clinical Trial: An Open Label Phase II Trial of BIBW 2992 in ...
The purpose of this trial is to evaluate the efficacy, safety and pharmacokinetics of BIBW 2992, a dual, irreversible EGFR- and HER2-inhibitor, ...
clinicaltrials.gov/ct/show/NCT00425854; jsessionid=9BD9036275E6D61A872727859FE7D77C?order= 35 - 18k - Cached - Similar pages
Xcovery blog - kinase industry knowledge collected and sometimes ...
Showing posts with label BIBW-2992. Show all posts. Showing posts with label BIBW-2992. ... BIBW-2992 - targeting EGFR and Her-2 BI-2536 - targeting Plk-1 ...
xcovery.blogspot.com/search/label/BIBW-2992 - 89k - Cached - Similar pages
Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase ...
Background: BIBW 2992 is a highly selective, potent, irreversible tyrosine inhibitor of EGFR and HER2. A phase 1 study of orally administered BIBW 2992 was ...
meeting.jco.org/cgi/content/abstract/24/18_suppl/3025 - Similar pages
A phase I dose escalation study of BIBW 2992, an irreversible dual ...
Background: BIBW 2992 is a novel, potent, orally bioavailable irreversible ... Methods: BIBW 2992 was administered orally as a continuous once daily dose ...
meeting.jco.org/cgi/content/abstract/24/18_suppl/2074 - Similar pages